Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 7/20 | 0.37 |
| ▸ | TP53 | P04637 | 6/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | LIPE | Q05469 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL764918 | 0.93 | MEN1 (0.40) | MEN1KMT2AMDM2TP53NPC1 | |
| SCHEMBL10042008 | 0.93 | MEN1 (0.43) | MEN1KMT2AMDM2TP53NPC1 | |
| SCHEMBL10041941 | 0.92 | MEN1 (0.43) | MEN1KMT2AMDM2TP53NPC1 | |
| SCHEMBL763401 | 0.90 | MEN1 (0.41) | MEN1KMT2AMDM2TGFBR1ACVR1 | |
| SCHEMBL764515 | 0.86 | MEN1 (0.41) | MEN1KMT2AMDM2TP53NPC1 | |
| SCHEMBL763877 | 0.85 | MEN1 (0.40) | MEN1KMT2AMDM2TP53NPC1 | |
| SCHEMBL763875 | 0.84 | MEN1 (0.39) | MEN1KMT2AMDM2TGFBR1ACVR1 | |
| SCHEMBL739297 | 0.79 | PTPN1 (0.47) | MEN1KMT2AMDM2TP53NPC1 | |
| SCHEMBL740876 | 0.78 | PTPN1 (0.47) | MEN1KMT2AMDM2TP53NPC1 | |
| SCHEMBL739352 | 0.78 | PTPN1 (0.47) | MEN1KMT2AMDM2TP53NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138184-B2 | Isoxazole derivatives and pharmaceutical compositions comprising the same | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2012-03-20 | — | — | US | disclosed |
| US-20090215768-A1 | ISOXAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215768-A1 | ISOXAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | TBXA2R, F12, PTH1R | MEN1 563/4885KMT2A 2590/4885MDM2 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.